References
- Djerassi I., Kim J. S., Nayak N. P. High-dose methotrexate with citrovorum factor rescue: A new approach to cancer chemotherapy. Recent Advances in Cancer Treatment, H. J. Tagnon, N. J. Staquet. Raven Press, New York 1977; 201–225
- Jolivet J., Cowan K. H., Curt G. A. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094–1104
- Evans W. E., Hutson P. R., Stewart C. F. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 1983; 33: 301–307
- Jacobs S. A., Stoller R. G., Chabner B. A. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976; 57: 534–538
- Fabre G., Goldman I. D. Formation of 7-hydroxymethotrexate polyglytamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro. Cancer Res 1985; 45: 80–85
- Von Hoff D. D., Penta J. S., Helman L. J. The incidence of drug related deaths secondary to high dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977; 61: 745–748
- Perez C., Sutow W. W., Wang Y. M. Evaluation of overall toxicity of high-dosage methotrexate regimens. Med Pediatr Oncol 1979; 6: 219–228
- Frei E, III, Blum R. H., Pitman S. W. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980; 68: 370–376
- Abelson H. T., Fosburg M. T., Beardsley G. P. Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983; 1: 208–216
- Jurgens H., Ebell W., Bachmann R. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue. Pediatr Pharmacol 1983; 3: 157–165
- Jaffe N., Takaue Y., Anzai T. Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 1985; 56: 1356–1360
- Doroshow J. H., Locker G. Y., Gaasterland D. E. Ocular irritation from high dose methotrexate therapy: Pharmacokinetics of drug in the tear film. Cancer 1981; 48: 2158–2162
- Doyle L. A., Berg C., Bottino G. Erythema and desquamation after high-dose methotrexate. Ann Intern Med 1983; 98: 611–612
- Urban C., Nirenberg A., Caparros B. Chemical pleuritis as the cause of acute chest pain following high-dose methotrexate. Cancer 1983; 51: 34–37
- Al Freeman, Weinberg V., Brecher M. L. Comparison of intermediate dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 1983; 308: 477–484
- Evans W. E., Crom W. R., Abromowitch M. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314: 471–477
- Moe P. J., Seip M., Finne P. H. Intermediate dose methotrexate in childhood acute lymphocytic leukemia. Eur Paediatr Haematol Oncol 1984; 1: 113–118
- Slørdal L., Prytz P. S., Pettersen I. Methotrexate measurements in plasma. Comparison of enzyme multiplied immunoassay technique, TDx fluorescence polarization immunoassay, and high pressure liquid chromatography. Ther Drug Monit 1986; 8: 368–372
- Pitman S. W., Parker L. M., Tattersall M. H. Clinical trial of high-dose methotrexate (NSC740) with citrovorum factor (NSC-3590): Toxicologic and therapeutic observations. Cancer Che-mother Rep 1975; 6: 43–49
- Stoller R. G., Hande K. R., Jacobs S. A. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630–634
- Breithaupt H., Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 1982; 66: 1733–1741
- Campbell M. A., Perrier D. G., Dorr R. T. Methotrexate: Bioavailability and pharmacokinetics. Cancer Treat Rep 1985; 69: 833–838
- Luyckx M., Cazin J. L., Brunet C. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses. Eur J Clin Pharmacol 1985; 28: 457–462
- Slørdal L., Kolmannskog S., Prytz P. S. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate after high-dose (33.6 g/m2) methotrexate therapy. Pediatr Hematol Oncol 1986; 3: 127–134